Immunome Inc. (NASDAQ:IMNM) saw director Jean Jacques Bienaime make a recent acquisition of company shares, an event often monitored by market analysts as an indicator of internal sentiment. On May 15, 2026, Mr. Bienaime purchased 5,000 shares of Immunome's common stock. The total value associated with this single transaction was reported to be $103,500.
The purchase utilized a weighted average price of $20.70 per share, though the actual executed prices varied slightly, ranging from a low of $20.645 up to $20.72. This acquisition increases Mr. Bienaime's direct holdings in Immunome common stock to 43,415 shares.
This transaction occurred against a backdrop of mixed market performance for IMNM. The stock had experienced a decline of 12% over the preceding week. However, looking at a longer time horizon, the shares have shown substantial appreciation, having surged by 148% over the past year. From an analytical perspective, data compiled through InvestingPro suggests that the stock is currently trading near what the platform defines as its Fair Value.
Beyond the insider activity and current market valuation metrics, Immunome Inc. has also reported significant clinical and regulatory progress concerning its drug candidate, varegacestat. The company has successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). This application centers on treating adults diagnosed with desmoid tumors.
The supporting evidence for this NDA comes from data generated during the Phase 3 RINGSIDE trial. This clinical study involved a cohort of 156 patients and provided key findings regarding varegacestat's efficacy. Specifically, the results demonstrated an 84% reduction in the risk of either disease progression or death when compared against a placebo group. The statistical significance was further highlighted by a hazard ratio of 0.16 and a p-value that was less than 0.0001.
These positive developments are set to gain further visibility, as Immunome also announced that the data from the RINGSIDE trial will be presented at an upcoming professional medical meeting. The presentation is scheduled for the American Society of Clinical Oncology Annual Meeting and will be delivered by Dr. Mrinal M. Gounder, who is affiliated with Memorial Sloan Kettering Cancer Center.
Risks
- <li style="margin-bottom: 10px;"><strong>Regulatory Uncertainty:</strong> The ultimate approval of varegacestat is contingent upon the FDA's review process following the NDA submission, which introduces regulatory risk.</li>
- <li style="margin-bottom: 10px;"><strong>Market Volatility:</strong> Despite strong clinical data and insider buying, the stock experienced a 12% decline over the past week, indicating potential short-term market volatility or investor caution.</li>
More from Insider Trading
Risks
- <li style="margin-bottom: 10px;"><strong>Regulatory Uncertainty:</strong> The ultimate approval of varegacestat is contingent upon the FDA's review process following the NDA submission, which introduces regulatory risk.</li>
- <li style="margin-bottom: 10px;"><strong>Market Volatility:</strong> Despite strong clinical data and insider buying, the stock experienced a 12% decline over the past week, indicating potential short-term market volatility or investor caution.</li>